Financials and Estimates

Financials and Estimates

EPAM's three-year record shows a business whose reported growth and reported earnings have moved in opposite directions. Revenue rose 15.4% in 2025 to $5.46 billion, yet GAAP net income fell 16.9% to $378 million and diluted EPS dropped from $7.84 to $6.72 [1]. Most of that gap is the mechanics of self-funded acquisitions, not core deterioration. This chapter lays out the numbers behind the divergence and what management and consensus expect next.

Source: FY2025 Annual Report (Form 10-K), Consolidated Statements of Income [2]; Q4/FY2025 earnings release, non-GAAP reconciliation [3].

The three-year record

Reported revenue tells a story of renewed growth: $4.69 billion in 2023, $4.73 billion in 2024, and $5.46 billion in 2025 [4]. The step-up in 2025 is real, but its source matters: the year-over-year increase came primarily from the fourth-quarter-2024 acquisitions of NEORIS and First Derivative, which added 9.2 percentage points to reported growth, with currency adding a further 1.3 points [5].

Source: FY2021–FY2025 Annual Reports, Consolidated Statements of Income [6].

Profitability moved the other way. GAAP operating margin peaked at 14.4% in 2021 — a boom year with an unusually low 9.7% tax rate — and has since settled into a lower band, from 11.9% (2022) to 10.7% (2023), 11.5% (2024), and 9.5% in 2025 [7]. Net margin has compressed further, to 6.9% in 2025. The case is most sensitive to whether 9.5% is a cyclical trough or a structural reset; the year-by-year path below frames the question, and the section on 2026 guidance shows how management answers it.

Source: derived from reported financials, FY2021–FY2025 Annual Reports [8].

Why 2025 earnings fell as revenue rose

The 16.9% decline in GAAP net income — from $454.5 million to $377.7 million — is only partly an operating-margin story. Income from operations fell $24.6 million, held down by a surge in depreciation and amortization to $124.8 million from $89.6 million as acquired intangibles began amortizing [9]. The larger swing sat below the operating line. Interest and other income, net collapsed to $11.5 million from $46.9 million as EPAM spent down its cash pile on those same acquisitions, and the foreign-exchange loss widened to $25.9 million from $7.0 million [10].

Source: Q4/FY2025 earnings release, Consolidated Statements of Income; components computed from the same statement [11].

Read that way, roughly a third of the earnings decline is operating and two-thirds is the below-the-line cost of buying growth: lost interest income on cash converted into two businesses, plus a currency headwind. That distinction matters for the investment case, because foregone interest income and a one-year FX loss are not the same kind of problem as an eroding services margin.

Cash generation reinforces the point. Free cash flow of $613 million in 2025 exceeded GAAP net income by 62%, because the earnings figure absorbs large non-cash charges — $124.8 million of depreciation and amortization and roughly $177 million of stock-based compensation — that do not leave the business [12]. Operating cash flow rose 17% to $655 million even as reported profit fell. The balance sheet behind these flows — roughly $1.3 billion of net cash and negligible debt — is treated in Fallen Star.

Reported growth versus organic growth

Because acquisitions and currency drive so much of the reported line, the cleaner gauge of underlying demand is organic constant-currency growth, which strips both out. On that basis 2025 grew 4.9%, against 15.4% reported [13]. That split is the pivot of the valuation case: EPAM's operating business trades at roughly 5x free cash flow (enterprise value ~$3.3B on $613M of 2025 free cash flow), but ~$470M of the revenue that multiple capitalizes was just bought for $927M (62% of it goodwill) with net income since acquisition 'not material', and only 4.9% of 2025's 15.4% reported growth was organic constant-currency. The deal economics behind that figure — the goodwill share and the ~2x sales paid — are treated in Margin of Safety; here the split simply marks how much of the reported line is bought. The quarter-by-quarter path is the more useful signal for the organic base: organic growth troughed near 1% in late 2024 and re-accelerated through 2025.

Sources: quarterly earnings calls — Q4 2024 [14], Q1 2025 [15], Q2 2025 [16], Q3 2025 [17]; Q4/FY2025 release [18].

Management attributes the improvement to a broad-based return to demand across all six verticals and all three regions, and to early traction in AI-related work; growth was positive in every vertical in 2025, led by Financial Services at 24.1% of revenue [19]. The counter-reading is that mid-single-digit organic growth is a long way from the 20%-plus rates EPAM posted before 2022, and that whether it holds — or is undercut by AI-driven pricing pressure — is unresolved. That debate is the subject of later chapters; the record here simply establishes that the organic base is growing again, not shrinking. Client concentration also stayed low, with the top five clients at 13.7% of revenue, down from 15.8% [20].

GAAP versus adjusted earnings

The gap flagged in Fallen Star — GAAP diluted EPS of $6.72 against non-GAAP diluted EPS of $11.50 — widened in 2025, and the direction of the two measures diverged. While GAAP net income fell 16.9%, non-GAAP net income rose to $646.8 million from $630.0 million, and non-GAAP EPS climbed to $11.50 from $10.86 [21]. The entire reported-earnings decline is a GAAP phenomenon; on the adjusted basis the company still grew.

Sources: FY2024–FY2025 actuals and FY2026 guidance midpoint, Q4/FY2025 earnings release non-GAAP reconciliation [22]; FY2026 guidance [23].

What sits inside the $311.5 million of adjustments to operating income deserves a closer look, because not all of it is the same quality. The largest single item is stock-based compensation of about $177 million — a genuine, recurring economic cost of a talent business, and the piece a skeptic would refuse to add back. Amortization of acquired intangibles more than doubled, to $71.4 million, and is non-cash but reflects real capital deployed on acquisitions. Cost-optimization (restructuring) charges of $47.9 million are labelled non-recurring, yet EPAM has run such a program in 2023, 2024, and again in 2025, which makes the "one-time" characterization generous [24]. Ukraine humanitarian support of $14.6 million is the most defensibly one-off.

Source: Q4/FY2025 earnings release, non-GAAP adjustment detail; stock comp combines cost-of-revenue and SG&A components [25].

A conservative investor should treat stock-based compensation as a true cost. Deducting the full $177 million from the adjusted figure still leaves earnings well above the GAAP number, so the two measures bracket a range rather than one being simply right: GAAP understates cash economics through non-cash amortization, while the adjusted figure flatters the multiple by adding back genuine, recurring compensation. The honest read of the year is that operating earnings power held roughly flat while the acquisition machinery and currency pushed the headline GAAP number down.

What the estimates and guidance imply

Management's own 2026 guidance answers the trough-or-reset question directly. It calls for GAAP operating margin to recover to 10.0%–11.0% from 9.5%, GAAP diluted EPS of $7.95–$8.25 (a roughly 20% rebound from $6.72), and non-GAAP diluted EPS of $12.60–$12.90 [26]. Revenue growth is guided to 4.5%–7.5%, of which organic constant currency is 3.0%–6.0%, with essentially no further acquisition contribution and a modest currency drag [27]. In other words, 2026 is guided as a self-help margin-recovery year on organically-driven growth, not another acquisition-fuelled top line.

Sources: FY2025 actuals and FY2026 company guidance, Q4/FY2025 earnings release [28] [29]; FY2026 consensus per aggregated analyst estimates.

Consensus sits at the optimistic end of that frame. Nineteen analysts model 2026 revenue of about $5.73 billion (5.0% growth) and non-GAAP EPS of $13.05, just above the top of the company's own guidance range, rising to $14.15 on $6.06 billion of revenue in 2027. Current-year EPS estimates have been revised up by 16 analysts and down by none over the past 30 days — a positive-revision trend, though 2027 estimates are more mixed. The visible expectation, then, is a return to steady high-single-digit adjusted-EPS growth on mid-single-digit revenue growth, with per-share figures further supported by the buyback that reduced diluted shares to 56.2 million in 2025 from 58.0 million [30].

The wide range of price targets captures how contested that outlook is. Against a current price of $86.38, the 19 published targets run from $85 at the low to $235 at the high, with a mean of $139 and a median of $135; the rating split is three strong-buy, eight buy, eight hold, and no sells. The implied multiples are undemanding on the estimates that hold up — roughly 10.7 times the midpoint of 2026 GAAP EPS guidance, and about 6.6 times consensus 2026 non-GAAP EPS — but those multiples are only as good as the mid-single-digit organic growth and margin recovery the estimates assume. The valuation lens itself belongs to Fallen Star and later chapters; the estimates simply mark where the debate is priced.

Source: aggregated analyst estimates and price targets (19 analysts); current price as of mid-July 2026.

The numbers here set up the chapters that follow: the top line is growing again organically, cash generation is intact, and the GAAP earnings dip is largely acquisition mechanics — but the margin recovery and the durability of organic growth are assumptions, not facts.